Wouter Pos
Wouter Pos
Verified email at uniqure.com
Cited by
Cited by
In vivo discovery of immunotherapy targets in the tumour microenvironment
P Zhou, DR Shaffer, DAA Arias, Y Nakazaki, W Pos, AJ Torres, ...
Nature 506 (7486), 52-57, 2014
Binding mode prediction of cytochrome P450 and thymidine kinase protein− ligand complexes by consideration of water and rescoring in automated docking
C De Graaf, P Pospisil, W Pos, G Folkers, NPE Vermeulen
Journal of medicinal chemistry 48 (7), 2308-2318, 2005
Crystal structure of the HLA-DM–HLA-DR1 complex defines mechanisms for rapid peptide selection
W Pos, DK Sethi, MJ Call, MSED Schulze, AK Anders, J Pyrdol, ...
Cell 151 (7), 1557-1568, 2012
An autoantibody epitope comprising residues R660, Y661, and Y665 in the ADAMTS13 spacer domain identifies a binding site for the A2 domain of VWF
W Pos, JTB Crawley, R Fijnheer, J Voorberg, DA Lane, BM Luken
Blood 115 (8), 1640-1649, 2010
Residues Arg568 and Phe592 contribute to an antigenic surface for anti-ADAMTS13 antibodies in the spacer domain
W Pos, N Sorvillo, R Fijnheer, HB Feys, PHP Kaijen, G Vidarsson, ...
haematologica 96 (11), 1670-1677, 2011
Amino acid regions 572–579 and 657–666 of the spacer domain of ADAMTS13 provide a common antigenic core required for binding of antibodies in patients with acquired TTP
BM Luken, EAM Turenhout, PHP Kaijen, MJ Greuter, W Pos, ...
Thrombosis and haemostasis 96 (09), 295-301, 2006
VH1‐69 germline encoded antibodies directed towards ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura
W Pos, BM Luken, JA Kremer Hovinga, EAM Turenhout, F Scheiflinger, ...
Journal of thrombosis and haemostasis 7 (3), 421-428, 2009
Molecular mechanisms for contribution of MHC molecules to autoimmune diseases
LM Sollid, W Pos, KW Wucherpfennig
Current opinion in immunology 31, 24-30, 2014
Mechanisms of peptide repertoire selection by HLA-DM
W Pos, DK Sethi, KW Wucherpfennig
Trends in immunology 34 (10), 495-501, 2013
The macrophage mannose receptor promotes uptake of ADAMTS13 by dendritic cells
N Sorvillo, W Pos, LM van den Berg, R Fijnheer, L Martinez-Pomares, ...
Blood, The Journal of the American Society of Hematology 119 (16), 3828-3835, 2012
Humoral immune response to ADAMTS13 in acquired thrombotic thrombocytopenic purpura
W Pos, BM Luken, N Sorvillo, JAK Hovinga, J Voorberg
Journal of thrombosis and haemostasis 9 (7), 1285-1291, 2011
Identification of N‐linked glycosylation and putative O‐fucosylation, C‐mannosylation sites in plasma derived ADAMTS 13
N Sorvillo, PH Kaijen, M Matsumoto, Y Fujimura, C van der Zwaan, ...
Journal of Thrombosis and Haemostasis 12 (5), 670-679, 2014
AT1412, a Patient-Derived Antibody in Development for the Treatment of CD9 Positive Precursor B-Acute Lymphoblastic Leukemia
G De Jong, SE Levie, R Schotte, W Pos, D Go, E Yasuda, M Cercel, ...
Blood, The Journal of the American Society of Hematology 134 (Supplement_1 …, 2019
14 A patient derived antibody targeting the tetraspanin CD9 inhibits tumour progression and metastasis
R Schotte, J Villaudy, E Verdegaal, D Go, C Fatmawati, C Bru, ...
ESMO Open 3 (Suppl 2), A6-A7, 2018
The role of MHC class II polymorphisms for DM-mediated peptide editing and autoimmunity
S Haag, W Pos, J Pyrdol, SK Dougan, KW Wucherpfennig
The Journal of Immunology 198 (1 Supplement), 156.24-156.24, 2017
580P AT1412, a patient-derived CD9 antibody promotes tumour immune infiltration and induces tumour rejection
R Schotte, J Villaudy, M Kedde, W Pos, K Wagner, D Go, C Fatmawati, ...
Annals of Oncology 31, S492, 2020
582P Preclinical development of AT1412, a patient derived CD9 antibody that does not induce thrombosis for treatment of precursor B ALL
J Villaudy, R Schotte, G de Jong, V Neviani, W Pos, S Levie, E Yasuda, ...
Annals of Oncology 31, S493, 2020
AT1412, a patient-derived antibody in development for the treatment of CD9-positive precursor B-acute lymphoblastic leukemia
G de Jong, SE Levie, R Schotte, W Pos, D Go, E Yasuda, M Cercel, ...
Cancer Research 80 (16 Supplement), 531-531, 2020
A patient-derived anti-CD9 antibody induces tumor rejection and synergistically enhances anti-PD1 activity
R Schotte, J Villaudy, M Kedde, W Pos, K Wagner, V Neviani, D Go, ...
Cancer Research 80 (16 Supplement), 532-532, 2020
Implications for tetraspanin-enriched microdomain assembly based on structures of CD9 with EWI-F
W Oosterheert, KT Xenaki, V Neviani, W Pos, S Doulkeridou, ...
bioRxiv, 2020
The system can't perform the operation now. Try again later.
Articles 1–20